Unraveling the Abbreviated Development Path

Publication of the Public Consultation for the review of RDC 200 - what is new?

NEW REGULATORY FRAMEWORK OF API

Six suggestions for a successful Advisory Board

What is the purpose of clinical research on health products?

Incremental innovations - what are the financial benefits?

Incremental innovation: 5 suggestions that can contribute to your success

What are the new expectations for the development of incremental products and medicines?

INCREMENTAL INNOVATION: How to prepare for the changes that will come with the revision of RDC 200

COVID-19: What facilities is ANVISA providing at this time of crisis?

Why are 24% of drug registrations still rejected?

Cannabis: challenges and opportunities

API, BPF and drug dossier - How to align the processes to ensure success in registration?

NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?

Publication of the new API regulatory framework: what is essential to know?

What is important about the new regulatory framework for good manufacturing practices?

Cannabis for therapeutic uses: is this a new market?

Outcome of the RDC 200 Review Working Group meeting - 02/05/20

Cannabis: the rules of the new regulation system.

Everything you need to know about the new rules for Drug Renewal.